Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors

Background Omacetaxine mepesuccinate is indicated in adults with chronic myeloid leukemia resistant and/or intolerant to ≥ 2 tyrosine kinase inhibitor treatments. This phase I study assessed the disposition, elimination, and safety of (14)C-omacetaxine in patients with solid tumors. Methods The stud...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Invest New Drugs
Egile Nagusiak: Nijenhuis, Cynthia M., Hellriegel, Edward, Beijnen, Jos H., Hershock, Diane, Huitema, Alwin D. R., Lucas, Luc, Mergui-Roelvink, Marja, Munteanu, Mihaela, Rabinovich-Guilatt, Laura, Robertson, Philmore, Rosing, Hilde, Spiegelstein, Ofer, Schellens, Jan H. M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer US 2016
Gaiak:
Phase I Studies
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5007276/
https://ncbi.nlm.nih.gov/pubmed/27221729
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0360-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak